EP2454265A2 — Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
Assigned to Rigel Pharmaceuticals Inc · Expires 2012-05-23 · 14y expired
What this patent protects
The present disclosure provides biologically active deuterated 2,4-pyrimidinediamine compounds <1> Formula (1) and prodrugs thereof, compositions comprising the deuterated compounds, intermediates and methods for synthesizing the deuterated compounds and methods of using th…
USPTO Abstract
The present disclosure provides biologically active deuterated 2,4-pyrimidinediamine compounds <1> Formula (1) and prodrugs thereof, compositions comprising the deuterated compounds, intermediates and methods for synthesizing the deuterated compounds and methods of using the deuterated compounds in a variety of applications.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.